Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Dr Reddys unveils generic version of Nitropress injection in US

      Dr Reddys unveils generic version of Nitropress injection in US

      Farhat Nasim30 Dec 2019 4:13 PM IST
      Sodium Nitroprusside injection, 50 mg/2 ml (25 mg/ml) is a generic version of Hospira Inc's Nitropress injection, 50 mg/2ml, it added, Dr Reddy's said...
      Johnson and Johnson gets Chinese nod to import psoriasis drug Tremfya

      Johnson and Johnson gets Chinese nod to import psoriasis drug Tremfya

      Farhat Nasim29 Dec 2019 9:30 AM IST
      Johnson and Johnson (JnJ) is positioning Tremfya as a better alternative to Novartis’s Cosentyx as it seeks to take market share away from the...
      JnJ to pay Rs 230 crore fine for not passing GST rate cut benefits to customers

      JnJ to pay Rs 230 crore fine for not passing GST rate cut benefits to customers

      Farhat Nasim28 Dec 2019 4:03 PM IST
      New Delhi: Healthcare major, Johnson and Johnson (JnJ) recently landed in soup after the National Anti-profiteering Authority (NAA) found that its...
      Indira IVF to invest Rs 80 crore to expand presence in south India by 2020

      Indira IVF to invest Rs 80 crore to expand presence in south India by 2020

      Farhat Nasim28 Dec 2019 10:00 AM IST
      "With 81 centres currently spread across the county, we would be coming up with 15-20 new centres in south India. We would be investing around Rs...
      IIT-Roorkee develops bioresorbable, economical ortho implants to heal bone fractures

      IIT-Roorkee develops bioresorbable, economical ortho implants to heal bone fractures

      Farhat Nasim28 Dec 2019 9:40 AM IST
      The current therapeutic strategies for healing bone defects commonly suffer from the occurrence of bacterial contamination on the graft, resulting in...
      Immunomedics BLA resubmission for sacituzumab govitecan to treat breast cancer accepted by USFDA

      Immunomedics BLA resubmission for sacituzumab govitecan to treat breast cancer accepted by USFDA

      Farhat Nasim28 Dec 2019 9:10 AM IST
      Sacituzumab govitecan has been awarded both Fast Track Designation and Breakthrough Therapy Designation by the USFDA, Immunomedics said in its recent...
      Zydus Cadila to divest two major units- Vivo, Gynova for Rs 1200 crore: Report

      Zydus Cadila to divest two major units- Vivo, Gynova for Rs 1200 crore: Report

      Farhat Nasim27 Dec 2019 1:12 PM IST
      New Delhi: Envisioning to off-load the burden of debts, one of India's top drugmakers- Zydus Cadila aka Cadila Healthcare is likely to vend its...
      Astellas Pharma acquires Xyphos for USD 665 million

      Astellas Pharma acquires Xyphos for USD 665 million

      Farhat Nasim27 Dec 2019 9:25 AM IST
      Japan's second-biggest drugmaker by sales paid $120 million upfront for Xyphos and the rest will be milestone payments, Astellas Pharma and Xyphos...
      What Makes Group Medical Insurance Cheaper than Individual Insurance

      What Makes Group Medical Insurance Cheaper than Individual Insurance

      Farhat Nasim26 Dec 2019 2:27 PM IST
      The rise in health-related issues has made buying medical insurance a necessity for everyone. But many people find it hard to afford because of other...
      Sunovion Pharma resubmits application to USFDA for sublingual Apomorphine to treat Parkinsons disease

      Sunovion Pharma resubmits application to USFDA for sublingual Apomorphine to treat Parkinsons disease

      Farhat Nasim25 Dec 2019 9:15 AM IST
      New Delhi: Sunovion Pharmaceuticals Inc. (Sunovion) recently announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug...
      After Cipla, Glenmark Digihaler secures NPPA nod for separate price; Details

      After Cipla, Glenmark Digihaler secures NPPA nod for separate price; Details

      Farhat Nasim23 Dec 2019 4:28 PM IST
      New Delhi: The National Pharmaceuticals Pricing Authority (NPPA) recently approved the price for the digital dose counter brand ’Digihaler’...
      Cadila Healthcare Gujarat facility clears USFDA inspection

      Cadila Healthcare Gujarat facility clears USFDA inspection

      Farhat Nasim22 Dec 2019 9:30 AM IST
      "We hereby inform that the USFDA inspected the Company’s topical manufacturing facility located in Ahmedabad from 16th to 20th December 2019," Cadila...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok